他汀类药物预防缺血性卒中的作用研究进展

被引:30
作者
郭亚东
徐安定
机构
[1] 暨南大学附属第一医院神经内科
关键词
缺血性卒中; 他汀类; 出血性卒中; 动脉粥样硬化斑块; 药物预防; 化学预防;
D O I
暂无
中图分类号
R743 [脑血管疾病]; R54 [心脏、血管(循环系)疾病];
学科分类号
1002 ; 100201 ;
摘要
<正>脑卒中具有高复发率和高死亡率的特点,其中缺血性卒中具有更高的发病率,如何有效地预防缺血性卒中的发生具有积极的意义。近年来的研究强化了血脂与缺血性卒中的关系,其中研究的焦点为低密度脂蛋白(LDL)水平与缺血性卒中之
引用
收藏
页码:1 / 3
页数:3
相关论文
共 10 条
[1]  
Statins in Stroke Prevention and Carotid Atherosclerosis: Systematic Review and Up-to-Date Meta-Analysis[J] . Pierre Amarenco,Julien Labreuche,Philippa Lavallée,Pierre-Jean Touboul.Stroke . 2004 (12)
[2]  
Blood pressure, haemorrhagic stroke, and ischaemic stroke: the Korean national prospective occupational cohort study[J] . Yun-Mi Song,Joohon Sung,Debbie A Lawlor,George Davey Smith,Youngsoo Shin,Shah Ebrahim.BMJ: British Medical Journal . 2004 (7435)
[3]   Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease [J].
Seljeflot, I ;
Tonstad, S ;
Hjermann, I ;
Arnesen, H .
ATHEROSCLEROSIS, 2002, 162 (01) :179-185
[4]  
Further evidence for direct vascular actions of statins: Effect on endothelial nitric oxide synthase and adhesion molecules[J] . A. Mueck,H. Seeger,D. Wallwiener.Exp Clin Endocrinol Diabetes . 2001 (03)
[5]  
Reduction of Stroke Incidence After Myocardial Infarction With Pravastatin: The Cholesterol and Recurrent Events (CARE) Study[J] . Jonathan F. Plehn,Barry R. Davis,Frank M. Sacks,Jean L. Rouleau,Marc A. Pfeffer,Victoria Bernstein,T. Edward Cuddy,Lemuel A. Moye,Linda B. Piller,John Rutherford,Lara M. Simpson,Eugene Braunwald.Circulation . 1999 (2)
[6]   Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells [J].
Pietsch, A ;
Erl, W ;
Lorenz, RL .
BIOCHEMICAL PHARMACOLOGY, 1996, 52 (03) :433-439
[7]  
Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts[J] . The Lancet . 1995 (8991)
[8]  
High-dose atorvastatin after stroke or transient ischemic attack. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels(SPARCL)Investigators. The New England Journal of Medicine . 2006
[9]  
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study Group. Lancet, The . 1994
[10]  
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. Nissen S E, Tuzcu E M, Schoenhagen P, et al. Journal of the American Medical Association, The . 2004